What’s at stake: Callaghan Innovation business unit GlycoSyn has worked with more than 100 drug companies worldwide to develop ingredients that are the key constituents of vaccines, antivirals, and rare disease therapies.
Background: GlycoSyn was born in 2003 out of the former IRL’s Carbohydrate Chemistry Team led by Professors Richard Furneaux and Peter Tyler – who later shifted to the Ferrier Institute.
Main players: GlycoSyn, Callaghan Innovation, the Ferrier Institute at Victoria University.
Molybdenum Cofactor Deficiency (MoCD) is a rare, genetic metabolic disorder that typically presents in the first few days of someone’s life. It causes seizures, brain injury, and death.
MoCD patients can’t produce a substance known as cyclic pyrantoperin monophosphate. In 2010, New Zealand
Want to read more? It's easy.
Choose your best value subscription option
Student
Exclusive offer for uni students studying at a New Zealand university (valued at $499).
What’s at stake: Callaghan Innovation business unit GlycoSyn has worked with more than 100 drug companies worldwide to develop ingredients that are the key constituents of vaccines, antivirals, and rare disease therapies.
Background: GlycoSyn was born in 2003 out of the former IRL’s Carbohydrate Chemistry Team led by Professors Richard Furneaux and Peter Tyler – who later shifted to the Ferrier Institute.
Main players: GlycoSyn, Callaghan Innovation, the Ferrier Institute at Victoria University.